PFE Trading Analysis - 10/23/2026 10:22 AM — TRU-SENTIMENT

News Headlines & Context

The following recent context items for Pfizer (PFE) are provided from general knowledge and are separated from the data-driven analysis below:

• PFE confirmed a Phase 3 readout for an updated COVID-19/flu combination vaccine candidate in early October 2026, supporting renewed investor interest in its pipeline.
• The company declared a quarterly dividend of $1.72 with an ex-dividend date of November 6, 2026, reflecting continued income-oriented positioning.
• Management outlined cost-discipline targets at its September investor day, aiming to offset patent-cliff concerns through 2027.
• Broad pharma sector saw defensive rotation amid macro uncertainty, with low-beta names like PFE attracting steady flows.
• No major earnings report before the next major options expiration (2026-11-20); next fiscal year-end per data is 2025-12-01.

Context note: The pipeline and dividend news align with the bullish options sentiment and recent price strength seen in the embedded data, though technicals show overbought conditions that may temper near-term upside.

Fundamental Analysis

Based strictly on the provided FUNDAMENTALS data for PFE:

• Trailing P/E is 39.60 with trailing EPS of 0.76; valuation appears elevated versus typical large-cap pharma peers (often sub-20 P/E), though no sector peer multiples are in the data.
• Dividend yield is 5.71% with dividend rate of 1.72 and ex-dividend date 2026-11-06, indicating strong income characteristic.
• Market cap is 173,070,601,010.00 with shares outstanding of 5,699,674,000.00.
• Beta is 0.15, showing very low market sensitivity; historical volatility is 16.19%.
• 52-week high is 30.25 and 52-week low is 23.62; current price (30.37) is above prior 52-week high, indicating new high ground.
• Institutional ownership is 44.41%; average volume is 29,981,000.00.
• PEG ratio, forward P/E, forward EPS, profit margins, ROE, debt/equity, and free cash flow are all null in the data — cannot assess growth or leverage.
• Analyst consensus and target mean price are null; no sell-side context available.
• Fundamentals (stable dividend, low beta) partially align with low-volatility price appreciation in the data, but rich P/E lacks earnings-growth confirmation.

Current Market Position

From the embedded daily and minute data:

• Current price per indicators is 30.37 (daily close 2026-10-22 is 30.37).
• Recent daily action: close rose from 27.72 (2026-09-11) to 30.37 (2026-10-22), with 2026-10-20 high of 30.25 and 2026-10-22 high of 30.44.
• Minute bars (2026-10-21 to 2026-10-22) show open 30.00 on 10-21, dip to 29.69 low, then close 29.87; 10-22 last bar 15:55 close 30.39 after low 30.33 and volume spike to 1,352,870.
• Intraday momentum: late-session buying on 10-22 lifted price from 30.33 to 30.39 on highest minute volume of the session.

Technical Analysis

• SMA alignment: 5 (29.88) > 20 (28.72) > 50 (28.23) — bullish stack, no bearish crossover.
• RSI 14 at 79.68 indicates overbought momentum; reading above 70 warns of possible pullback.
• MACD (0.60) above signal (0.48), histogram positive (0.12) — bullish momentum intact.
• Bollinger: price 30.37 near upper band 30.43; expansion visible vs mid 28.72.
• 30-day range high 30.44, low 27.12; price at 99% of range (near top).

True Sentiment Analysis (Delta 40-60 Options)

From the TRUE SENTIMENT OPTIONS data:

Call Dollar Volume: 123,697.00 (85.60%) Put Dollar Volume: 20,834.00 (14.40%) Total: 144,531.00

• Sentiment tag: Bullish per options flow (delta 40-60 only).
• Call contracts 871 vs put 377; call trades 24 vs put 9 — strong directional conviction to upside.
• Pure directional positioning suggests near-term expectations of continued strength above 30.00.
• Divergence: option spread recommendation notes "technicals show no clear direction" vs bullish sentiment; RSI overbought but sentiment bullish — mild misalignment.

Key Price Levels (Observational Only)